Altimmune (ALT) Other financing activities (2011 - 2026)
Altimmune (ALT) posted quarterly Other financing activities of $177000.0 for Q1 2026, up 4.12% year-over-year from $170000.0 in Q1 2025, and down 37.46% quarter-over-quarter from $283000.0 in Q3 2025.
Powered by 
Analysis
Altimmune (ALT) Other financing activities (2011 - 2026) Analysis & Trends
Altimmune (ALT) has reported Other financing activities for 15 consecutive years, with $177000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 4.12% year-over-year to $177000.0; the TTM figure through Mar 2026 stood at $298000.0 (up 83.95% YoY), while the FY2025 annual figure was $291000.0, up 80.75% from the prior year.
- Other financing activities declined to $177000.0 in Q1 2026 per ALT's latest filing, from $283000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $755000.0 in Q3 2022 and bottomed at -$162000.0 in Q2 2025.
- Historically, Other financing activities has averaged $153818.2 across 5 years, with a median of $113000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other financing activities tumbled 46.02% — and 2025, when it jumped 3637.5%.
- Altimmune's Other financing activities stood at $82000.0 in 2022, then sank by 36.59% to $52000.0 in 2023, then tumbled by 115.38% to -$8000.0 in 2024, then surged by 3637.5% to $283000.0 in 2025, then slumped by 37.46% to $177000.0 in 2026.
- Business Quant data shows ALT's Other financing activities at $177000.0 in Q1 2026, $283000.0 in Q3 2025, and -$162000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -686,000.00 |
| Mar 31, 2026 | 177,000.00 |
| Sep 30, 2025 | 797,000.00 |
| Jun 30, 2025 | -676,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 93,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 169,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 268,000.00 |
| Jun 30, 2022 | 487,000.00 |
| Mar 31, 2022 | 113,000.00 |
| Sep 30, 2021 | 119,000.00 |
| Mar 31, 2021 | 106,000.00 |
| Sep 30, 2020 | 9.73 Mn |
| Jun 30, 2020 | 31.25 Mn |
| Mar 31, 2020 | 56,739.00 |